Validity of the 5-fluorouracil plasma concentration in patients having a chemotherapy regime with 5 -fluorouracil

Validity of the 5-fluorouracil plasma concentration in patients having a chemotherapy regime with 5 -fluorouracil - CHEVAL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011486

Enrollment

800

Registered

2016-12-21

Start date

2017-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C26.0

Interventions

Group 1: The study group are patients receiving a 5- fluorouracil therapy regime During a therapy cycle a venous blood sample is obtained between 18 and 22 hours after start of the infusion for the de

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. Signed informed consent 3. Having chemotherapy with 5-FU

Exclusion criteria

Exclusion criteria: 1. Age < 18 years 2. No informed consent

Design outcomes

Primary

Measure	Time frame
Aim is to estmate the 5-fluorouracil exposition in comparison to the 5-fluorouracil dosage	—

Secondary

Measure	Time frame
Relationship between 5-fluorouracil exposition and toxicity	—

Countries

Germany

Contacts

Public ContactRalf-Dieter Hofheinz

TagesTherapieZentrum am Interdisziplinären Tumorzentrum MannheimUniversitätsmedizin Mannheim

ralf.hofheinz@umm.de+49 621 383 2855

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026